期刊文献+

基因工程抗体anti-HBsAgFab原核表达体系大规模培养条件的实验研究 被引量:4

Conditions for large-scale production of genetically engineered E.coli bearing humanized anti- HBsAg Fab
暂未订购
导出
摘要 目的探讨含anti-HBsAg Fab/pBAD表达载体的工程化大肠杆菌的大规模培养条件。方法在摇瓶发酵条件下探讨工程菌的生长和表达规律,摸索最佳的培养模式及诱导表达条件。后根据摇瓶发酵结果于发酵罐中行补料高密度发酵试验,确定最佳补料模式。结果由摇瓶发酵获得的数据表明,以培养体系处于对数生长中期为诱导表达的起点、在25 ℃条件下以0.2% 阿拉伯糖诱导12 h,Fab的得率最佳,采用溶氧控制补料模式可使培养体系的最大D600达到55.2,相当于湿菌含量110 g/L水平;同时,经证实Fab的抗原结合活性良好。结论初步确定了周期短、产率高且稳定可靠的发酵工艺路线,为应用原核表达体系工业化大批量生产基因工程抗体奠定了基础。 Objective To define the conditions for large-scale production of genetically engineered E.coli bearing humanized anti-HBsAg Fab. Method Characteristic growth and expression of the engineered E.coli were observed during fermentation in the shaking flask to define the optimal culture conditions to achieve the highest production levels. On the basis of the observation results, the E.coli was cultured in a fermentor using the fed-batch method to determine the optimal production techniques. Results Observation of the bacterium in the shaking flask showed initiation of the induction procedure in the mid-log growth phase at 25 ℃ with 0.2% arabinose resulted in the highest production of anti-HBsAg Fab. The D600 value of the culture reached 55.2, equivalent to 110 g/L wet weight of the bacterium, using the DO-stat fed-batch method. The resultant Fab showed well-preserved biological activity. Conclusion Reliable techniques for rapid and massive production of the Fab have been developed.
出处 《第一军医大学学报》 CSCD 北大核心 2004年第5期517-520,共4页 Journal of First Military Medical University
基金 国家自然科学基金(39670668)~~
关键词 基因工程抗体 anti-HBsAgFab 原核表达 实验研究 优化表达 engineered antibody Fab Escherichia coli high-cell-density cultivation (HCDC) optimized expression
  • 相关文献

参考文献10

  • 1Lee SY. High cell-density culture ofEscherichia coli [J]. Trends Biotechnol, 1996, 14(3): 98-105.
  • 2Makrides SC. Strategies for achieving high-level expression of genes in Escherichia coli[J]. Microbiol Rev, 1996, 60(3): 512-38.
  • 3李仲宏,麦国丰,罗荣城,李爱民.瘤内注射核素标记混合抗体治疗肝癌的实验研究[J].第一军医大学学报,2000,20(4):327-328. 被引量:5
  • 4罗荣城,尤长宣,韩焕兴,胡栋平,王传斌,苏瑾.人源乙型肝炎病毒表面抗原抗体Fab片段与IFN-α融合蛋白表达载体的筛选[J].第一军医大学学报,2000,20(2):100-102. 被引量:2
  • 5Riesenberg D, Menzel K, Schulz V, et al. High-cell density fermentation of recombinant Escherichia coli. Expressing human interferon alpha[J]. Appl Microbio Biotechnol, 34(1): 77-82.
  • 6Pluckthun A, Krebber A. Producing antibodies in Escherichia coli:from PCR to fermentation [A]. In: McCaffergy J, Hoogenboon H,Chiswell D, eds. Antibody Engineering: A Practical Approach [M].Oxford: Oxford University Press, 2001. 203-52.
  • 7Luli GW, Strohl WR. Comparison of growth, acetate, production and acetate inhibition of Escherichia coli. Strains in batch and fedbatch fermentation[J]. Appl Environ Microbiol, 1990, 56(4): 1004-11.
  • 8Guzman LM, Belin D, Carso MJ, et al. Tight regulation, modulation,and high-level expression by vectors containing the arabinose pBAD promoter[J]. J Bacteriol, 177(54): 4121-30.
  • 9Horn V, Strittmatter W. High volumetric yields of functional dimeric miniantibodies in Escherichia coli. Using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions[J]. Appl Microbiol Biotechnol, 46(3): 524-32.
  • 10Clark MA, Hammond FR, Papaioannou A, et al. Regulation and expression of human Fab under the control of the Escherichia coli arabinose promoter, pBAD [J]. Immunotechnology, 1997, 3 (3): 217-26.

二级参考文献6

共引文献5

同被引文献35

  • 1Shi-Chun Lu, Lu-Nan Yan, Bo Li, Tian-Fu Wen, Ji-Chun Zhao, Nan-Sheng Cheng, Chong Liu, Jun Liu, Xiao-Bo Wang, Xiao-Dong Li, Shan Qin, Lian-Shan Zhao, Bin-Jun Lei and Xiu-Hui Zhang Chengdu, China Department of Surgery ,Viral Hepa- titis Research Center ,Department of Pathology , West China Hospital, Sichuan University, Cheng- du 610041 , China.Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation[J].Hepatobiliary & Pancreatic Diseases International,2004,3(1):26-32. 被引量:9
  • 2郑树森.积极推进我国肝脏移植的发展[J].中华肝脏病杂志,2004,12(6):321-322. 被引量:4
  • 3浦宇,王芝祥.蛋白质层析用离子交换和疏水作用层析介质的发展概况[J].生物工程学报,2004,20(6):975-982. 被引量:6
  • 4唐莉,曾志贵,潘桃,袁劲,陈必成,陈忠华,陈知水.抗HBsAg-Fab重组体在小鼠肝脏的表达[J].世界华人消化杂志,2006,14(16):1554-1560. 被引量:2
  • 5Cheng Suna; Jian-Wen Wanga; I.ei Fanga; et al. , Free radical scavenging and antioxidant aetlvitles of EPS2, an exopolysaccharide produced by a marine filamentous fungus Keisslefiella sp. YS 4108,Life Sciences ,2004,75 : 1063-1073.
  • 6Thomas Ouellette; Sophie Destrau; Timothy Ouellette; et al. ,Production and purification of refolded recombinant human IL-7 from inclusion bodies, Protein Expression and Purification, 2003 , (30):156-166.
  • 7Youngjin Byun; Marl Ohmura; Kohtaro Fujihashi; et al. , Nasal immunization with E. eoli verotoxin 1 (VT1)-B subunit and a nontoxie mutant of eholera toxin elicits serum neutralizing antibodies ,Vaccine, 2001,19 : 2061-2070.
  • 8Qi Gaofu; Mao Dan; Wu Jie; et al. , Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants , Vaccine, 2004 , (22):3187-3194.
  • 9Daan J. A. Crommelin; Gert Storm; Ruud Verrijk; et al. , Shifting paradigms: biopharmaeeuticals versus low molecular weight drugs,International Journal of Pharmaceuties, 2003, (266) :3-16.
  • 10Helena Engman; Christer Tannergren; Per Artursson; et al. ,Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caeo-2 cell monolayers, European Journal of Pharmaceutical Sciences, 2003, (9) : 57-65.

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部